Q3 2025 Earnings Call Transcript November 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-1.40538, expectations were $-1.91. Operator: Good morning, ladies and ...
H. Lundbeck A/S (Lundbeck) today announced the acceptance of its new drug application (NDA) for Vyepti® (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback